Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 6/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11364946 | 0.93 | PTGER4 (0.48) | PTGER4PTGER2PTGER3KMT2AMEN1 | |
| SCHEMBL635958 | 0.89 | PTGER4 (0.40) | PTGER4PTGER2PTGER3KMT2AP2RX7 | |
| SCHEMBL1865254 | 0.87 | PTGER4 (0.52) | PTGER4PTGER2PTGER3KMT2AMEN1 | |
| SCHEMBL2034493 | 0.83 | PTGER4 (0.36) | PTGER4PTGER2PTGER3KMT2AP2RX7 | |
| SCHEMBL10750938 | 0.82 | PTGER4 (0.57) | PTGER4PTGER2PTGER3KMT2AMEN1 | |
| SCHEMBL13651410 | 0.80 | PER2 (0.42) | KMT2AP2RX7 | |
| SCHEMBL2782894 | 0.80 | PER2 (0.42) | KMT2AP2RX7 | |
| SCHEMBL12298852 | 0.80 | PTGER4 (0.52) | PTGER4PTGER2PTGER3KMT2AMEN1 | |
| SCHEMBL12993185 | 0.80 | PTGER4 (0.52) | PTGER4PTGER2PTGER3KMT2AMEN1 | |
| SCHEMBL13205695 | 0.79 | PTGER4 (0.42) | PTGER4PTGER2PTGER3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120269750-A1 | COSMETIC COMPOSITIONS COMPRISING AN ESTER DERIVED FROM 4-CARBOXY-2-PYRROLIDINONE AND A LIPOPHILIC SCREENING AGENT; USE OF SAID DERIVATIVE AS A SOLVENT FOR A BENZOPHENONE LIPOPHILIC SCREENING AGENT | L'OREAL (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2496207-A1 | COSMETIC COMPOSITIONS COMPRISING AN ESTER DERIVED FROM 4-CARBOXY-2-PYRROLIDINONE AND A LIPOPHILIC SCREENING AGENT; USE OF SAID DERIVATIVE AS A SOLVENT FOR A BENZOPHENONE LIPOPHILIC SCREENING AGENT | L'Oréal (FR) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011054388-A1 | COSMETIC COMPOSITIONS COMPRISING AN ESTER DERIVED FROM 4-CARBOXY-2-PYRROLIDINONE AND A LIPOPHILIC SCREENING AGENT; USE OF SAID DERIVATIVE AS A SOLVENT FOR A BENZOPHENONE LIPOPHILIC SCREENING AGENT | L'OREAL (FR) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269750-A1 | COSMETIC COMPOSITIONS COMPRISING AN ESTER DERIVED FROM 4-CARBOXY-2-PYRROLIDINONE AND A LIPOPHILIC SCREENING AGENT; USE OF SAID DERIVATIVE AS A SOLVENT FOR A BENZOPHENONE LIPOPHILIC SCREENING AGENT | C1S, PAH, CYP51A1 | PTGER4 193/4885PTGER2 256/4885PTGER3 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.